Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans
JB Bulitta, WW Hope, AE Eakin, T Guina… - Antimicrobial agents …, 2019 - Am Soc Microbiol
ABSTRACT In June 2017, the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
the National Institutes of Health, organized a workshop entitled “Pharmacokinetics …
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens
AM Sandri, CB Landersdorfer, J Jacob… - Clinical infectious …, 2013 - academic.oup.com
Background. Polymyxin B is a last-line therapy for multidrug-resistant gram-negative
bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients …
bacteria. There is a dearth of pharmacokinetic data to guide dosing in critically ill patients …
Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of …
M Boisson, M Jacobs, N Grégoire, P Gobin… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Colistin is an old antibiotic that has recently gained a considerable renewal of interest for the
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …
treatment of pulmonary infections due to multidrug-resistant Gram-negative bacteria …
Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models
CB Landersdorfer, J Wang, V Wirth… - Journal of …, 2018 - academic.oup.com
Background The pharmacokinetic/pharmacodynamic (PK/PD) relationship for polymyxin B
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …
against Klebsiella pneumoniae infections is not known. Methods Dose-fractionation studies …
Clinical population pharmacokinetics and toxicodynamics of linezolid
LM Boak, CR Rayner, ML Grayson… - Antimicrobial agents …, 2014 - Am Soc Microbiol
Thrombocytopenia is a common side effect of linezolid, an oxazolidinone antibiotic often
used to treat multidrug-resistant Gram-positive bacterial infections. Various risk factors have …
used to treat multidrug-resistant Gram-positive bacterial infections. Various risk factors have …
Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling
Bacterial resistance is among the most serious threats to human health globally, and many
bacterial isolates have emerged that are resistant to all antibiotics in monotherapy …
bacterial isolates have emerged that are resistant to all antibiotics in monotherapy …
[HTML][HTML] Functionalisation of brush polyethylene glycol polymers with specific lipids extends their elimination half-life through association with natural lipid trafficking …
M Abdallah, L Lin, IK Styles, A Mörsdorf, JL Grace… - Acta Biomaterialia, 2024 - Elsevier
Polymeric prodrugs have been applied to control the delivery of various types of
therapeutics. Similarly, conjugation of peptide therapeutics to lipids has been used to …
therapeutics. Similarly, conjugation of peptide therapeutics to lipids has been used to …
Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance
Infections caused by multidrug-resistant Acinetobacter baumannii are a major public health
problem, and polymyxins are often the last line of therapy for recalcitrant infections by such …
problem, and polymyxins are often the last line of therapy for recalcitrant infections by such …
Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability …
Pseudomonas aeruginosa remains a challenge in chronic respiratory infections in cystic
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …
fibrosis (CF). Ceftolozane-tazobactam has not yet been evaluated against multidrug …
[HTML][HTML] Using machine learning to optimize antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter …
NM Smith, JR Lenhard, KR Boissonneault… - Clinical Microbiology …, 2020 - Elsevier
Objectives Increased rates of carbapenem-resistant strains of Acinetobacter baumannii have
forced clinicians to rely upon last-line agents, such as the polymyxins, or empirical …
forced clinicians to rely upon last-line agents, such as the polymyxins, or empirical …